PATIENT FILE: Subject ID: BF-0934

Name: Redacted (Formerly: “Marion D.”)
DOB: unknown
Admission: 11 SE / Intake 11.22
Current Status: DISCHARGED

SUMMARY:
Subject BF-0934 was admitted under Ascendant Fold directive for preliminary screening as a Vessel Candidate. Initial intake notes describe high physical resilience and stable psychological baseline, raising expectations of compatibility. Consent documentation is incomplete—signed only by proxy witnesses, without recorded personal assent.

TREATMENTS ADMINISTERED:

• Baseline marrow extraction and re-seeding trial (Protocol V-Δ).
• Endocrine manipulation via targeted pituitary modulation.
• Sub-dermal resonance mapping with limited phase induction cycles.
• Psychological endurance testing through deprivation chambers and repetitive stimulus-response trials.

OBSERVED EFFECTS:

• Mild increase in regenerative capacity (12% over baseline).
• Unstable hormonal feedback; adrenal-pituitary axis collapsed after extended modulation.
• Subject displayed high pain tolerance but no measurable resonance attunement.
• Increasing psychological distress during testing, culminating in repeated refusal to comply with induction cycles.

RATIONALE FOR DISCHARGE:
After twelve weeks of observation, BF-0934 did not meet threshold requirements for transfer to Resurgens Theta. Specifically, marrow responsiveness and neural resonance coupling fell well below committee standards for First Vessel candidacy. Prognosis for long-term survival under integration procedures was deemed negligible.

NOTES (Classified):
“Marked as a ‘failed trial.’ Subject released from secure care under standard discharge protocols. Records sealed at request of Project Oversight. No further follow-up authorized. Disposal or assimilation into civilian population remains unverified.” — Dr. K. Malvek, Project Lead